Extracorporeal blood purification for sepsis

Hong Kong Medical Journal

Volumn 22, Issue 5, 2016, Pages 478-485

  Shum, H P ^a   Yan, W W ^a   Chan, T M ^b  

^a PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; POLY(METHYL METHACRYLATE); POLYMYXIN B; AUTACOID; BACTERIAL TOXIN;

ACUTE KIDNEY FAILURE; CELL MIGRATION; CONTINUOUS HEMOFILTRATION; EXTRACORPOREAL BLOOD PURIFICATION; HEMOPERFUSION; HUMAN; META ANALYSIS (TOPIC); MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; SCORING SYSTEM; SEPSIS; SEPTIC SHOCK; HEMOFILTRATION; ISOLATION AND PURIFICATION; PROCEDURES;

ACUTE KIDNEY INJURY; BACTERIAL TOXINS; HEMOFILTRATION; HUMANS; INFLAMMATION MEDIATORS; SEPSIS;

EID: 84990927920     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: 10.12809/hkmj164876     Document Type: Review

References (77)

1. Shum HP, Yan WW, Chan TM. Recent knowledge on the pathophysiology of septic acute kidney injury: A narrative review. J Crit Care 2016;31:82-9.
2. Cole L, Bellomo R, Hart G, et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002;30:100-6.
3. Payen D, Mateo J, Cavaillon JM, et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009;37:803-10.
4. Prince LR, Whyte MK, Sabroe I, Parker LC. The role of TLRs in neutrophil activation. Curr Opin Pharmacol 2011;11:397-403.
5. Nakayama H, Kurokawa K, Lee BL. Lipoproteins in bacteria: structures and biosynthetic pathways. FEBS J 2012;279:4247-68.
6. Zarbock A, Gomez H, Kellum JA. Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies. Curr Opin Crit Care 2014;20:588-95.
7. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;369:2063.
8. Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock 2014;41:3-11.
9. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN 1412. N Engl J Med 2006;355:1018-28.
10. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008;300:413-22.
11. Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011;306:2594-605.
12. Wang C, Sun J, Zheng J, et al. Low-dose hydrocortisone therapy attenuates septic shock in adult patients but does not reduce 28-day mortality: a meta-analysis of randomized controlled trials. Anesth Analg 2014;118:346-57.
13. Kalil AC, Sun J. Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies. Intensive Care Med 2011;37:420-9.
14. Alejandria MM, Lansang MA, Dans LF, Mantaring JB III. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2013;(9):CD001090.
15. Bernard GR, Francois B, Mira JP, et al. Evaluating the efficacy and safety of two doses of the polyclonal antitumor necrosis factor-alpha fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study. Crit Care Med 2014;42:504-11.
16. Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003;27:792-801.
17. Honoré PM, Matson JR. Extracorporeal removal for sepsis: Acting at the tissue level—the beginning of a new era for this treatment modality in septic shock. Crit Care Med 2004;32:896-7.
18. Di Carlo JV, Alexander SR. Hemofiltration for cytokinedriven illnesses: the mediator delivery hypothesis. Int J Artif Organs 2005;28:777-86.
19. Peng Z, Singbartl K, Simon P, et al. Blood purification in sepsis: a new paradigm. Contrib Nephrol 2010;165:322-8.
20. Rimmelé T, Kellum JA. Clinical review: blood purification for sepsis. Crit Care 2011;15:205.
21. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301:2445-52.
22. Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 2003;7:108-14.
23. Mitaka C, Tomita M. Polymyxin B–immobilized fiber column hemoperfusion therapy for septic shock. Shock 2011;36:332-8.
24. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B–immobilized fiber column in sepsis: a systematic review. Crit Care 2007;11:R47.
25. Zhou F, Peng Z, Murugan R, Kellum JA. Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med 2013;41:2209-20.
26. Payen DM, Guilhot J, Launey Y, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 2015;41:975-84.
27. Iwagami M, Yasunaga H, Doi K, et al. Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis. Crit Care Med 2014;42:1187-93.
28. Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials 2014;15:218.
29. Ullrich H, Jakob W, Frohlich D, et al. A new endotoxin adsorber: first clinical application. Ther Apher 2001;5:326-34.
30. Staubach KH, Boehme M, Zimmermann M, Otto V. A new endotoxin adsorption device in Gram-negative sepsis: use of immobilized albumin with the MATISSE adsorber. Transfus Apher Sci 2003;29:93-8.
31. Reinhart K, Meier-Hellmann A, Beale R, et al. Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected Gram-negative sepsis. Crit Care Med 2004;32:1662-8.
32. Kulabukhov VV. Use of an endotoxin adsorber in the treatment of severe abdominal sepsis. Acta Anaesthesiol Scand 2008;52:1024-5.
33. Yaroustovsky M, Abramyan M, Popok Z, et al. Preliminary report regarding the use of selective sorbents in complex cardiac surgery patients with extensive sepsis and prolonged intensive care stay. Blood Purif 2009;28:227-33.
34. Ala-Kokko TI, Laurila J, Koskenkari J. A new endotoxin adsorber in septic shock: observational case series. Blood Purif 2011;32:303-9.
35. Shum HP, Leung YW, Lam SM, Chan KC, Yan WW. Alteco endotoxin hemoadsorption in Gram-negative septic shock patients. Indian J Crit Care Med 2014;18:783-8.
36. Harm S, Falkenhagen D, Hartmann J. Endotoxin adsorbents in extracorporeal blood purification: do they fulfill expectations? Int J Artif Organs 2014;37:222-32.
37. Taniguchi T. Cytokine adsorbing columns. Contrib Nephrol 2010;166:134-41.
38. Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M. Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med 2008;36:268-72.
39. Kobe Y, Oda S, Matsuda K, Nakamura M, Hirasawa H. Direct hemoperfusion with a cytokine-adsorbing device for the treatment of persistent or severe hypercytokinemia: a pilot study. Blood Purif 2007;25:446-53.
40. Tsuchida K, Takemoto Y, Sugimura K, Yoshimura R, Nakatani T. Direct hemoperfusion by using Lixelle column for the treatment of systemic inflammatory response syndrome. Int J Mol Med 2002;10:485-8.
41. Morris C, Gray L, Giovannelli M. Early report: The use of CytoSorb haemabsorption column as an adjunct in managing severe sepsis: initial experiences, review and recommendations. J Intensive Care Soc 2015;16:257-64.
42. Hinz B, Jauch O, Noky T, Friesecke S, Abel P, Kaiser R. CytoSorb, a novel therapeutic approach for patients with septic shock: a case report. Int J Artif Organs 2015;38:461-4.
43. Wiegele M, Krenn CG. CytoSorb in a patient with Legionella pneumonia–associated rhabdomyolysis: a case report. ASAIO J 2015;61:e14-6.
44. Hetz H, Berger R, Recknagel P, Steltzer H. Septic shock secondary to beta-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy. Int J Artif Organs 2014;37:422-6.
45. Bouman CS, van Olden RW, Stoutenbeek CP. Cytokine filtration and adsorption during pre-and postdilution hemofiltration in four different membranes. Blood Purif 1998;16:261-8.
46. De Vriese AS, Colardyn FA, Philippé JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999;10:846-53.
47. Hirasawa H, Oda S, Matsuda K. Continuous hemodiafiltration with cytokine-adsorbing hemofilter in the treatment of severe sepsis and septic shock. Contrib Nephrol 2007;156:365-70.
48. Mitzner S, Schneidewind J, Falkenhagen D, Loth F, Klinkmann H. Extracorporeal endotoxin removal by immobilized polyethylenimine. Artif Organs 1993;17:775-81.
49. Shum HP, Chan KC, Kwan MC, Yan WW. Application of endotoxin and cytokine adsorption haemofilter in septic acute kidney injury due to Gram-negative bacterial infection. Hong Kong Med J 2013;19:491-7.
50. Turani F, Candidi F, Barchetta R, et al. Continuous renal replacement therapy with the adsorbent membrane oXiris in septic patients: a clinical experience. Crit Care 2013;17 Suppl 2:63.
51. Matsuda K, Hirasawa H, Oda S, Shiga H, Nakanishi K. Current topics on cytokine removal technologies. Ther Apher 2001;5:306-14.
52. Nakada TA, Hirasawa H, Oda S, Shiga H, Matsuda K. Blood purification for hypercytokinemia. Transfus Apher Sci 2006;35:253-64.
53. Nakada TA, Oda S, Matsuda K, et al. Continuous hemodiafiltration with PMMA hemofilter in the treatment of patients with septic shock. Mol Med 2008;14:257-63.
54. Matsuda K, Moriguchi T, Harii N, Yanagisawa M, Harada D, Sugawara H. Comparison of efficacy between continuous hemodiafiltration with a PMMA high-performance membrane dialyzer and a PAN membrane hemofilter in the treatment of septic shock patients with acute renal failure. Contrib Nephrol 2011;173:182-90.
55. Kellum JA, Mehta RL, Angus DC, Palevsky P, Ronco C, ADQI Workgroup. The first international consensus conference on continuous renal replacement therapy. Kidney Int 2002;62:1855-63.
56. Honore PM, Joannes-Boyau O, Boer W, Collin V. Highvolume hemofiltration in sepsis and SIRS: current concepts and future prospects. Blood Purif 2009;28:1-11.
57. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume haemofiltration in human septic shock. Intensive Care Med 2001;27:978-86.
58. Boussekey N, Chiche A, Faure K, et al. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med 2008;34:1646-53.
59. Cornejo R, Downey P, Castro R, et al. High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 2006;32:713-22.
60. Joannes-Boyau O, Rapaport S, Bazin R, Fleureau C, Janvier G. Impact of high volume hemofiltration on hemodynamic disturbance and outcome during septic shock. ASAIO J 2004;50:102-9.
61. Piccinni P, Dan M, Barbacini S, et al. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med 2006;32:80-6.
62. Joannes-Boyau O, Honoré PM, Perez P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 2013;39:1535-46.
63. Lehner GF, Wiedermann CJ, Joannidis M. High-volume hemofiltration in critically ill patients: a systematic review and meta-analysis. Minerva Anestesiol 2014;80:595-609.
64. Clark E, Molnar AO, Joannes-Boyau O, Honoré PM, Sikora L, Bagshaw SM. High-volume hemofiltration for septic acute kidney injury: a systematic review and meta-analysis. Crit Care 2014;18:R7.
65. Haase M, Bellomo R, Morgera S, Baldwin I, Boyce N. High cut-off point membranes in septic acute renal failure: a systematic review. Int J Artif Organs 2007;30:1031-41.
66. Atan R, Crosbie D, Bellomo R. Techniques of extracorporeal cytokine removal: a systematic review of the literature. Blood Purif 2012;33:88-100.
67. Morgera S, Rocktäschel J, Haase M, et al. Intermittent high permeability hemofiltration in septic patients with acute renal failure. Intensive Care Med 2003;29:1989-95.
68. Morgera S, Haase M, Kuss T, et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006;34:2099-104.
69. Honore P, Beck W, editors. High cut-off continuous venovenous hemodialysis (CVVHD) in patients treated for acute renal failure after systemic inflammatory response syndrome (SIRS)/septic shock (HICOSS). Proceedings of the 10th Congress of the World Federation of Societies of Intensive and Critical Care Medicine (WFSICCM); 2009 Aug 28-Sep 1; Florence, Italy.
70. Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 2002;28:1434-9.
71. Reeves JH, Butt WW, Shann F, et al. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med 1999;27:2096-104.
72. Long EJ, Shann F, Pearson G, Buckley D, Butt W. A randomised controlled trial of plasma filtration in severe paediatric sepsis. Crit Care Resusc 2013;15:198-204.
73. Stegmayr B, Abdel-Rahman EM, Balogun RA. Septic shock with multiorgan failure: from conventional apheresis to adsorption therapies. Semin Dial 2012;25:171-5.
74. Formica M, Inguaggiato P, Bainotti S, Wratten ML. Coupled plasma filtration adsorption. Contrib Nephrol 2007;156:405-10.
75. Livigni S, Bertolini G, Rossi C, et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open 2014;4:e003536.
76. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
77. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014;311:1308-16.